A61K 40/50
Cellular immunotherapy: characterised by the use of allogeneic cells
Official title: characterised by the use of allogeneic cells
A61K40/50 (Cellular immunotherapy: characterised by the use of allogeneic cells) appears on 341 US grants and 842 published applications in this corpus.
Search patents in A61K- Granted patents
- 341
- Published applications
- 842
- Assignees
- 326
- Inventors
- 1,423
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 2 |
| 2002 | 6 | 8 |
| 2003 | 3 | 8 |
| 2004 | 2 | 15 |
| 2005 | 1 | 8 |
| 2006 | 2 | 11 |
| 2007 | 4 | 5 |
| 2008 | 3 | 9 |
| 2009 | 3 | 10 |
| 2010 | 5 | 7 |
| 2011 | 5 | 16 |
| 2012 | 5 | 9 |
| 2013 | 3 | 12 |
| 2014 | 15 | 15 |
| 2015 | 3 | 25 |
| 2016 | 13 | 19 |
| 2017 | 10 | 22 |
| 2018 | 23 | 39 |
| 2019 | 16 | 43 |
| 2020 | 25 | 42 |
| 2021 | 41 | 73 |
| 2022 | 35 | 101 |
| 2023 | 18 | 88 |
| 2024 | 23 | 97 |
| 2025 | 34 | 87 |
| 2026 | 27 | 71 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Methods for manufacturing genetically engineered CAR-T cells22 Sep 2026US 12,742,184 B2Crispr Therapeutics AG
- T cell receptors recognizing R273C or Y220C mutations in P531 Sep 2026US 12,721,890 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Methods of manufacturing CAR-T cells1 Sep 2026US 12,723,268 B2Crispr Therapeutics AG
- Methods and compositions for modulating CAR-T activity25 Aug 2026US 12,715,918 B2Sana Biotechnology, Inc.
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Treatment of autoimmune disorders using chimeric antigen receptor therapy1 Oct 2026US 2026/0295043 A1Novartis AG
- Patrolling monocyte cellular therapy1 Oct 2026US 2026/0297525 A1New York Blood Center, Inc.
Most cited
By later US patents
- Cancer immunotherapy using tumor cells combined with mixed lymphocytes81US 6,207,147 B1The Regents of the University of California · 2001
- Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene58US 9,889,160 B2Precision BioSciences, Inc. · 2018
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy55US 10,130,659 B2Iovance Biotherapeutics, Inc. · 2018
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy52US 10,363,273 B2Iovance Biotherapeutics, Inc. · 2019
- Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells45US 5,242,687 ATKB Associates Limited Partnership · 1993